NantKwest Announces Pricing of Initial Public Offering
July 28 2015 - 1:38AM
Business Wire
NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage
immunotherapy company focused on harnessing the power of the innate
immune system by using the natural killer cell to treat cancer,
infectious diseases and inflammatory diseases, announced today the
pricing of its initial public offering of 8,288,000 shares of its
common stock at a price to the public of $25.00 per share. All of
the shares are being offered by NantKwest. The shares are expected
to begin trading on The Nasdaq Global Select Market on July 28,
2015, under the symbol "NK." In addition, NantKwest has granted the
underwriters a 30-day option to purchase up to an additional
1,243,200 shares of its common stock. Concurrently with the initial
public offering, NantKwest is also selling 680,000 shares of its
common stock in a separate private placement to Celgene
Corporation, an existing stockholder, at the initial public
offering price of $25.00 per share.
BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC
and Piper Jaffray are acting as joint book-running managers for the
offering, and MLV & Co. LLC is acting as co-manager.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission and became
effective on July 27, 2015. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
The offering is being made only by means of a prospectus. A copy
of the final prospectus related to the offering may be obtained,
when available, from: BofA Merrill Lynch, 222 Broadway, New York,
NY 10038, Attention: Prospectus Department, or by email at
dg.prospectus_requests@baml.com; Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by email at prospectus@citi.com, or by telephone at
(800) 831-9146; Jefferies LLC, Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by telephone at (877) 547-6340, or by email at
Prospectus_Department@Jefferies.com; or Piper Jaffray & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, Suite 800,
Minneapolis, MN 55402, or by email at prospectus@pjc.com, or by
telephone at (800) 747-3924.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150727006420/en/
NantKwestJen Hodson, 562-397-3639jen@nantworks.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2023 to Apr 2024